RxDoctor Payments Data

Lupita Gallardo, MD

Family Medicine · Palm Harbor, FLNPI 1215270111

Payments from drug & device makers

$1,615in general payments, 2019–2025

Across 55 payments — averaging $29.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$502
  • Lilly USA, LLC$193
  • AstraZeneca$184
  • Novo Nordisk$174
  • Amgen$171
  • Pfizer$119
  • plus $272 from 7 others

What the payments were for

  • Food & beverage$1,60199%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,615 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$97,759
Medicare patients
232
Services billed
900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin20$32,450
RybelsusSemaglutide14$30,720
OzempicSemaglutide26$22,941
MounjaroTirzepatide22$22,907
VraylarCariprazine Hcl11$16,265
Levothyroxine Sodium249$3,490
Atorvastatin Calcium229$2,118
Rosuvastatin Calcium198$2,056
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,775
Losartan Potassium181$1,768
Albuterol Sulfate HfaAlbuterol Sulfate50$1,333
Amlodipine Besylate200$1,215
Mirtazapine38$1,128
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,093
SynthroidLevothyroxine Sodium21$1,056

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$174$53,66140 claims
Boehringer IngelheimJardiance$34$32,45020 claims
Lilly USA, LLCMounjaro$193$22,90722 claims
AbbVieVraylar, Synthroid$502$17,32132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Palm Harbor

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →